Smyth A, Teo KK, Rangarajan S, O'Donnell M, Zhang X, Rana P, Leong DP, Dagenais G, Seron P, Rosengren A, Schutte AE, Lopez-Jaramillo P, Oguz A, Chifamba J, Díaz R, Lear S, Avezum A, Kumar R, Mohan V, Szuba A, Wei L, Yang W, Jian B, McKee M, Yusuf S, PURE Investigators. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet 2015;386:1945-54. [Ref.ID 99672]

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43. [Ref.ID 91122]

Mann JFE, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Díaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S, for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes. A randomized trial. Ann Intern Med 2009;151:1-10. [Ref.ID 86256]

Mann JFE, Schmieder RE, Teo KK, Yusuf S, on behalf of the ONTARGET Investigators. Renal outcomes in the ONTARGET study. Authors' reply. Lancet 2008;372:2020-1. [Ref.ID 84769]

Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, on behalf of the ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53. [Ref.ID 83789]

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al.. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16. [Ref.ID 79804]

Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Zhang X, Yusuf S, on behalf of the INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-58. [Ref.ID 77827]

Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, Collins R, for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43. [Ref.ID 63582]

Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave A, Chang WC, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG, for the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Investigators. A randomized trial of the effect of community pharmacists intervention on cholesterol risk management. Arch Intern Med 2002;162:1149-55. [Ref.ID 62567]

Tsuyuki RT, McKelvie RS, Arnold JMO, Avezum A, Barretto ACP, Carvalho ACC, Isaac DL, Kitching AD, Piegas L S, Teo KK, Yusuf S. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337-42. [Ref.ID 59263]

McAlister FA, Lawson FME, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001;323:957-62. [Ref.ID 59245]

Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M, for the SHARE Investigators. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-84. [Ref.ID 52168]

Ackman ML, Bampbell JB, Buzak KA, Tsuyuki RT, Montague TJ, Teo KK. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother 1999;33:674-9. [Ref.ID 45085]

McAlister FA, Ackman ML, Tsuyuki RT, Kimber S, Teo KK, for the Clinicl Quality Improvement Network Investigators. Contemporary utilization of digoxin in patients with atrial fibrillation. Ann Pharmacother 1999;33:289-93. [Ref.ID 43857]

Teo KK. Cardiology. BMJ 1998;316:911-5. [Ref.ID 37344]

McAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 1997;54:235-52. [Ref.ID 33653]

Teo KK. Risk and management of hypertension-related left ventricular hypertrophy. Drugs 1995;50:959-70. [Ref.ID 25334]

Teo KK. Angiotensin converting enzyme genotypes and disease. BMJ 1995;311:763-4. [Ref.ID 24869]

Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95. [Ref.ID 20009]

Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991;303:1499-503. [Ref.ID 16533]